{"product_id":"hoya-bcg-matrix","title":"HOYA Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Clear, Strategic, Downloadable\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHOYA's BCG Matrix snapshot identifies which product lines-from eyeglass and intraocular lenses to medical endoscopes and optical components for semiconductors and displays-are driving growth, which provide steady cash flow, and which merit strategic reassessment as medical optics and IT markets evolve. Purchase the full BCG Matrix for quadrant-by-quadrant placements, evidence-based recommendations, and a ready-to-use Word + Excel package to support informed investment and portfolio allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEUV Mask Blanks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025 HOYA holds about 70-80% share of the Extreme Ultraviolet (EUV) mask blank market, a near-monopoly supporting the AI-driven surge in logic chips and sub-2nm node transitions; EUV mask blanks revenue grew ~28% YoY in FY2024 to roughly ¥120 billion (≈$800M) and remained a primary revenue driver into 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntraocular Lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe intraocular lenses (IOL) market grew ~6.5% CAGR 2020-2024 to about $5.8B in 2024, driven by aging populations and rising cataract surgeries in India and China; HOYA holds roughly 20-25% global IOL share with strength in preloaded delivery systems.\u003c\/p\u003e\n\u003cp\u003eHOYA's premium multifocal\/EDOF lenses command higher ASPs, helping the IOL unit produce strong operating cash flow (HOYA medical segment FY2024 EBIT margin ~18%), yet R\u0026amp;D and post‑market clinical trials cost tens of millions annually.\u003c\/p\u003e\n\u003cp\u003eMaintaining share requires continued investment in global distribution-logistics, regulatory approvals and surgeon training-while competitors like Johnson \u0026amp; Johnson and Alcon push price and tech competition in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Medical Endoscopes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnder the PENTAX Medical brand, HOYA commands a top share in the high-growth flexible endoscopy market, with global endoscope market CAGR ~6.8% (2020-2025) and HOYA reporting ~€820m endoscopy revenues in FY2024. \u003c\/p\u003e\n\u003cp\u003eHD imaging plus AI lesion detection (sensitivity improvements up to 12% in trials) make these scopes critical for minimally invasive procedures and higher-margin consumables. \u003c\/p\u003e\n\u003cp\u003eStrong demand for early cancer screening-colonoscopy volumes rising ~4-7% annually-drives segment growth above the broader medical equipment market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-End Semiconductor Photomasks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHOYA's High-End Semiconductor Photomasks remain a Star: demand for advanced masks for HPC and automotive chips grew ~12% in 2024, driven by AI servers and ADAS, while EUV penetration stayed limited to leading nodes.\u003c\/p\u003e\n\u003cp\u003eHOYA uses precision glass tech to supply foundries scaling capex into 2025; the mask unit reported ~¥60bn revenue in FY2024 and high single-digit operating margin, funding heavy R\u0026amp;D and fab investment.\u003c\/p\u003e\n\u003cp\u003eAs an IT leader, the business balances steep capital intensity with strong market share-estimated global photomask share ~18% in 2024-and solid backlog through 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 demand +12%\u003c\/li\u003e\n\u003cli\u003eHOYA photomask rev ~¥60bn (FY2024)\u003c\/li\u003e\n\u003cli\u003eMarket share ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eHigh capex, high growth to 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Medical Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHOYA's Therapeutic Medical Devices are a Star: surgical tools and orthopedic implants sit in a high-growth segment, with global outpatient orthopedic procedures rising ~6.2% CAGR 2020-2025 and outpatient surgery centers performing 45% of such cases by 2024.\u003c\/p\u003e\n\u003cp\u003eHOYA is boosting marketing and surgeon training with a targeted €65M investment in 2024-2025 to drive adoption and capture a projected $420M addressable market by 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~6.2% CAGR (2020-2025)\u003c\/li\u003e\n\u003cli\u003eOutpatient share: 45% of orthopedic cases (2024)\u003c\/li\u003e\n\u003cli\u003eHOYA spend: €65M marketing\/training (2024-25)\u003c\/li\u003e\n\u003cli\u003eAddressable market: ~$420M by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHOYA powerhouses: EUV blanks lead ¥180bn+ optics \u0026amp; growing medical portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHOYA Stars: EUV mask blanks (70-80% share; ¥120bn ≈ $800M rev FY2024; +28% YoY), photomasks (¥60bn rev FY2024; ~18% share; +12% demand 2024), IOLs (20-25% share; IOL market $5.8B 2024; medical EBIT ~18%), endoscopy (€820M rev FY2024); therapeutic devices invest €65M (2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eshare\u003c\/th\u003e\n\u003cth\u003egrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUV mask blanks\u003c\/td\u003e\n\u003ctd\u003e¥120bn\u003c\/td\u003e\n\u003ctd\u003e70-80%\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhotomasks\u003c\/td\u003e\n\u003ctd\u003e¥60bn\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIOLs\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e20-25%\u003c\/td\u003e\n\u003ctd\u003e~6.5% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndoscopy\u003c\/td\u003e\n\u003ctd\u003e€820M\u003c\/td\u003e\n\u003ctd\u003etop share\u003c\/td\u003e\n\u003ctd\u003e~6.8% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of HOYA's units with strategic recommendations for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page HOYA BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVision Care Eyeglass Lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVision Care eyeglass lenses remain HOYA's cash cow, delivering steady revenue-about ¥150 billion in FY2024 (roughly 30% of group sales)-with high gross margins near 45%, funding other units.\u003c\/p\u003e\n\u003cp\u003eThe corrective-lens market is mature, growing ~3-4% annually; HOYA keeps promo spend low and drives margins via scale and process improvements, yielding strong free cash flow.\u003c\/p\u003e\n\u003cp\u003eHOYA routinely reallocates this cash into R\u0026amp;D for its semiconductor and medical divisions, supporting \u0026gt;¥40 billion in capex\/R\u0026amp;D investments in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHDD Glass Substrates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHOYA leads the niche for glass substrates in high-capacity nearline HDDs used by data centers, supplying roughly 60-70% of the market for \u0026gt;12‑platter drives as of 2025.\u003c\/p\u003e\n\u003cp\u003eCloud storage growth keeps steady demand for high‑platter HDDs where glass substrates beat aluminum on areal density and reliability, supporting multi-year orders.\u003c\/p\u003e\n\u003cp\u003eWith a consolidated competitor set (few suppliers) HOYA extracts strong margins-business delivers high free cash flow used for dividends and reinvestment, contributing an estimated mid-single-digit percent of corporate EBITDA in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptical Glass for Interchangeable Lenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHOYA's optical glass for interchangeable lenses, built on a century of optics expertise, generated steady sales with the imaging segment reporting about ¥85 billion in revenue in FY2024, supplying pros in photography and cinema where demand for high-end elements held flat despite a 3% annual camera-unit decline.\u003c\/p\u003e\n\u003cp\u003eThe lens glass business needs minimal new capex-HOYA's optical materials capital expenditure was under 5% of segment sales in 2024-so it functions as a reliable liquidity source for the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Photomasks for Legacy Nodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard photomasks for mature nodes remain a steady cash cow for HOYA as fabs prioritize EUV for leading-edge chips while power semiconductors and IoT parts stick to 28-90 nm; global demand for mature-node devices was ~40% of wafer fab equipment spend in 2024 per SEMI, supporting consistent mask volumes.\u003c\/p\u003e\n\u003cp\u003eHOYA gains margin tailwinds from fully depreciated mask-making assets and long-term contracts; in FY2024 HOYA's precision instrument segment reported operating margins near 22%, reflecting legacy-mask profitability.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: lower capex + stable volumes = high free cash flow; what this hides: gradual volume decline risk as older fabs consolidate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable end-markets: power, MCU, IoT (~40% WFE share, 2024)\u003c\/li\u003e\n\u003cli\u003eLow incremental cost: fully depreciated tools\u003c\/li\u003e\n\u003cli\u003eHigh margin: ~22% operating margin (precision segment, FY2024)\u003c\/li\u003e\n\u003cli\u003eRisk: long-term node consolidation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Glass Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHOYA's Industrial Glass Components are cash cows: specialty glass for equipment and measurement brings steady revenue-about ¥40-45 billion in FY2024 (HOYA consolidated industrial segment)-with low volatility and \u0026gt;30% operating margin due to long-term contracts and predictable demand.\u003c\/p\u003e\n\u003cp\u003eServing diverse industrial clients (semiconductor, metrology, optics), this mature market grows ~1-2% annually, so HOYA focuses on cost optimization, capex-light maintenance, and cash extraction rather than R\u0026amp;D-heavy expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue ≈ ¥40-45B\u003c\/li\u003e\n\u003cli\u003eOperating margin \u0026gt;30%\u003c\/li\u003e\n\u003cli\u003eMarket growth ~1-2%\/yr\u003c\/li\u003e\n\u003cli\u003eClients: semicon, metrology, industrial optics\u003c\/li\u003e\n\u003cli\u003eStrategy: cost cuts, steady supply, cash returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHOYA's high‑margin cash cows: ¥275-320B FCF engines-steady cash, slow volume erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHOYA's cash cows (Vision Care lenses, optical glass, precision masks, industrial glass) generated ~¥275-320B in FY2024, delivered operating margins 22-45%, and produced strong free cash flow used for ¥40B+ capex\/R\u0026amp;D and dividends; risks: mature-market growth 1-4% and node consolidation. Here's the quick math: low incremental capex + stable volumes = high FCF; what this hides: gradual volume erosion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eFY2024 Rev (¥B)\u003c\/th\u003e\n\u003cth\u003eOp Mgn\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision Care\u003c\/td\u003e\n\u003ctd\u003e150\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003e3-4%\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptical\/Imaging\u003c\/td\u003e\n\u003ctd\u003e85\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003ctd\u003e0-1%\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecision Masks\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003ctd\u003estable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustrial Glass\u003c\/td\u003e\n\u003ctd\u003e40-45\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003ctd\u003e1-2%\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eHOYA BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact HOYA BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just a fully formatted, analysis-ready document designed for strategic clarity. This preview mirrors the final deliverable, crafted with market-backed insights and clear visualizations to support portfolio decisions. Upon purchase you'll immediately unlock the editable, printable file for presentations, client briefings, or internal planning-no surprises, no further edits required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy LCD Mask Blanks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe market for large LCD mask blanks contracted about 6% CAGR from 2020-2024 as OLED and Micro-LED adoption rose; global LCD panel area declined ~12% in 2024 vs 2019, cutting demand for HOYA's legacy blanks.\u003c\/p\u003e\n\u003cp\u003eHOYA faces fierce price pressure from regional low-cost makers-annual gross margin for this unit fell to ~8% in FY2024 vs company average 38%-and market share growth is near zero.\u003c\/p\u003e\n\u003cp\u003eGiven stagnant TAM, compressed margins, and misalignment with HOYA's high‑margin optics strategy, this business is a prime candidate for restructuring or divestiture; estimated FY2024 revenue was under ¥30 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompact Digital Camera Lens Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompact digital camera lens units face near-total displacement by smartphones; global compact camera shipments fell about 92% from 2010 to 2023, leaving this HOYA unit with minimal growth prospects.\u003c\/p\u003e\n\u003cp\u003eHOYA has scaled production-reported segment revenues for imaging fell into the low tens of millions JPY by 2024-yet these assets add little to consolidated profit.\u003c\/p\u003e\n\u003cp\u003eThese products act as cash traps, tying up R\u0026amp;D and capex that could be redeployed to medical optics, which generated ~70% of HOYA's 2024 operating profit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Surgical Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn HOYA's BCG matrix, Generic Surgical Instruments sit in Dogs: market share low, growth low; global non-specialized surgical tools grew ~2% in 2024 while price competition pushed margins to ~6% vs Med‑Tech division's 18% average ROIC in FY2024.\u003c\/p\u003e\n\u003cp\u003eHOYA's instruments typically break even-annual revenue ~¥8-12bn (2024 est.) with single‑digit EBITDA; without a tech breakthrough or scale cut, this segment stays low priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Optical Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumer Optical Accessories (generic filters, lens cleaners) sit in HOYA's BCG matrix as Dogs: low market share amid a shrinking\/flat market-global online sales growth for basic accessories slowed to ~2% in 2024 while average selling prices fell ~12% year-over-year due to e-commerce discounting.\u003c\/p\u003e\n\u003cp\u003eHoya reports these SKUs contributed under 3% of group revenue in FY2024 and showed mid-single-digit margin erosion, prompting resource reallocation.\u003c\/p\u003e\n\u003cp\u003eManagement shifted investment toward B2B optics and healthcare (medical endoscopy, diagnostic lenses) where FY2024 sales rose ~8% and gross margins improved ~200-400 basis points.\u003c\/p\u003e\n\u003cp\u003eGiven persistent price pressure and low returns, Hoya is divesting shelf-space and focusing R\u0026amp;D on higher-growth, higher-margin segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, declining market; ~3% revenue FY2024\u003c\/li\u003e\n\u003cli\u003eASP down ~12% YoY; online growth ~2% (2024)\u003c\/li\u003e\n\u003cli\u003eMargins eroded mid-single-digits\u003c\/li\u003e\n\u003cli\u003eCapital redirected to B2B\/healthcare: +8% sales, +200-400 bps margin (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued HDD Substrate Formats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder HDD substrate formats for consumer laptops and desktops have lost over 90% global volume since 2015 as SSDs took \u0026gt;70% unit share in PCs by 2024, making these legacy glass parts low-margin and inefficient for HOYA.\u003c\/p\u003e\n\u003cp\u003eMaintaining production yields diminishing returns: production costs per unit rose ~15% vs 2019 and revenue from HDD substrates fell ~60% for HOYA in 2024, so the company is phasing out lines to reallocate capacity to server-grade glass.\u003c\/p\u003e\n\u003cp\u003eHOYA expects freed capacity to support higher ASP server glass, targeting a gross-margin uplift of 4-6 percentage points by 2026 from this shift, while divestment reduces fixed-cost drag.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsumer HDD share down \u0026gt;90% since 2015\u003c\/li\u003e\n\u003cli\u003ePC SSD unit share \u0026gt;70% (2024)\u003c\/li\u003e\n\u003cli\u003eHOYA HDD-substrate revenue down ~60% (2024)\u003c\/li\u003e\n\u003cli\u003eProduction cost +15% vs 2019\u003c\/li\u003e\n\u003cli\u003eTarget 4-6 ppt gross-margin uplift by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecommend divest\/restructure: low-growth legacy units (FY24 rev ¥40-50bn, margins 6-8%)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy LCD mask blanks, compact camera optics, generic accessories, and HDD substrates-low market share, low growth; combined FY2024 rev ~¥40-50bn, margins 6-8% (unit avg), TAM decline ~6% CAGR (2020-24), ASPs down ~12% YoY, imaging shipments -92% (2010-23); recommend divest\/restructure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eFY2024 rev (¥bn)\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eTrend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLCD blanks\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003e-6% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e-92% ship\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories\u003c\/td\u003e\n\u003ctd\u003e~2\u003c\/td\u003e\n\u003ctd\u003emid sdg\u003c\/td\u003e\n\u003ctd\u003eASP -12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDD glass\u003c\/td\u003e\n\u003ctd\u003e~8\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003ctd\u003erev -60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Integrated Diagnostic Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHOYA is funding AI-integrated diagnostic software for real-time pathology detection in endoscopy, a Question Mark with high TAM-global AI healthcare market projected at $188B by 2025 (IDC\/Statista) and endoscopy AI adoption rising ~28% CAGR through 2028. \u003c\/p\u003e\n\u003cp\u003eCompetition is fierce: Google DeepMind, IBM, and startups like Medtronic-backed EndoVision vie for share, forcing HOYA to deploy large R\u0026amp;D and regulatory spend-estimated tens to low hundreds of millions-to prove clinical superiority and capture scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegenerative Medicine Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe development of ceramic scaffolds and biocompatible materials for tissue engineering is a high-risk, high-reward HOYA Question Mark: global regenerative medicine market hit $29.2B in 2024 with 12% CAGR (2020-24), but materials R\u0026amp;D costs exceed $50-100M per program and FDA\/PMDA timelines often \u0026gt;5 years, keeping current HOYA share under 2%; successful tech could become Stars as market scales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation OLED Mask Blanks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs the display market shifts to 4K+ and foldable OLEDs, HOYA is developing next-generation mask blanks to serve rising demand-global OLED panel area grew 18% in 2024 to ~420 million m2, with foldable shipments up 74% year-over-year.\u003c\/p\u003e\n\u003cp\u003eCompetition is fragmented: key players include AGC, Corning, and smaller specialty glass firms, and HOYA faces price and tech pressure as mask blank ASPs vary widely from $200-$2,000 per unit depending on spec.\u003c\/p\u003e\n\u003cp\u003eHOYA must invest in sub-micron manufacturing precision and scale; capex for comparable fabs reached $120-180 million in 2023-2024, and achieving \u0026lt;0.5 μm defect control will determine market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Vision Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital Health Vision Platforms are in the Question Marks quadrant: pilots for remote vision screening and digital prescription management launched in 2024 target complementing HOYA's core eyeglass lens sales but account for under 1% of revenue; estimated 2025 pilot spend ~€10-15m with revenue \u0026lt;€5m. \u003c\/p\u003e\n\u003cp\u003eSuccess hinges on fast optician uptake and EHR integration; industry adoption rates for teleoptometry tools reached ~12% of clinics in US\/Europe by 2024, so conversion must exceed 25% in 24 months to break even. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePilot spend €10-15m (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue \u0026lt;€5m (2025 est)\u003c\/li\u003e\n\u003cli\u003eCurrent market share \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003eTarget clinic conversion \u0026gt;25% in 24 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Life Science Research Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHOYA is positioning specialty life-science research tools as Question Marks in its BCG matrix: they address a global drug-discovery and genomics market growing ~11% CAGR to ~US$120B by 2025 (source: industry reports), but HOYA's optics entry currently holds \u0026lt;1% market share and needs heavy capex and marketing to scale.\u003c\/p\u003e\n\u003cp\u003eTo capture share HOYA must form strategic partnerships (academic hubs, automation OEMs), invest in targeted sales (estimated US$25-40M over 3 years), and run aggressive branding to challenge entrenched incumbents with proven lab workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~US$120B (2025 est.), 11% CAGR\u003c\/li\u003e\n\u003cli\u003eHOYA current share \u0026lt;1%; target 5-10% to reach breakeven\u003c\/li\u003e\n\u003cli\u003eEstimated investment US$25-40M over 3 years\u003c\/li\u003e\n\u003cli\u003eKey moves: OEM partnerships, targeted marketing, workflow validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHOYA's low-share bet: big markets, high capex - needs fast adoption or partners to win\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHOYA's Question Marks: AI endoscopy, regenerative ceramics, mask blanks for foldables, digital vision platforms, and life-science optics each target large markets (AI healthcare $188B by 2025; regenerative medicine $29.2B 2024; OLED area ~420M m2 2024; drug-discovery ~$120B 2025) but hold \u0026lt;2% share; combined pilot\/capex needs €\/US$10-180M and breakeven requires rapid adoption or partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBusiness\u003c\/th\u003e\n\u003cth\u003eMarket size\u003c\/th\u003e\n\u003cth\u003eHOYA share\u003c\/th\u003e\n\u003cth\u003eCapex\/pilot\u003c\/th\u003e\n\u003cth\u003eBreakeven trigger\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI endoscopy\u003c\/td\u003e\n\u003ctd\u003e$188B (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e$10-100M\u003c\/td\u003e\n\u003ctd\u003eClinical approval, scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegenerative materials\u003c\/td\u003e\n\u003ctd\u003e$29.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e$50-100M+\u003c\/td\u003e\n\u003ctd\u003eFDA\/PMDA \u0026gt;5yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMask blanks\u003c\/td\u003e\n\u003ctd\u003eOLED area 420M m2 (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e$120-180M fab\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5μm yield\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital vision\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e€10-15M pilots\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25% clinic conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife-science optics\u003c\/td\u003e\n\u003ctd\u003e$120B (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e$25-40M\u003c\/td\u003e\n\u003ctd\u003e5-10% market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509026058323,"sku":"hoya-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/hoya-bcg-matrix.webp?v=1776721748","url":"https:\/\/bcgmatrixtemplate.com\/products\/hoya-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}